HER4 expression in estrogen receptor-positive breast cancer is associated with decreased sensitivity to tamoxifen treatment and reduced overall survival of postmenopausal women

URN to cite this document:: urn:nbn:de:bvb:355-epub-384044
DOI to cite this document:: 10.5283/epub.38404

Wege, Anja Kathrin ; Chittka, Dominik ; Buchholz, Stefan ; Klinkhammer-Schalke, Monika ; Diermeier-Daucher, Simone ; Zeman, Florian ; Ortmann, Olaf ; Brockhoff, Gero

Preview

License: Creative Commons Attribution 4.0
PDF
(1MB)

Date of publication of this fulltext: 01 Mar 2019 12:00

Alternative links to fulltext:DOI Publisher Publisher

Details

Preview

Indexed in

Export bibliographical data

Abstract

BackgroundThe sensitivity of estrogen receptor-positive breast cancers to tamoxifen treatment varies considerably, and the molecular mechanisms affecting the response rates are manifold. The human epidermal growth factor receptor-related receptor HER2 is known to trigger intracellular signaling cascades that modulate the activity of coregulators of the estrogen receptor which, in turn, reduces ...